Fut, nem toboroz3. fázis
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Key facts
- Where
- Angers, Bron, Lille Cedex, Marseille, Paris és Toulouse Cedex 9, FranciaországSee the 7 sites
- Phase
- 3. fázis
Where in Franciaország
- Centre Hospitalier Universitaire D'AngersAngers, FranciaországNo longer taking part
- Hospital Femme Mere EnfantBron, FranciaországNo longer taking part
- Centre Hospitalier Universitaire De LilleLille Cedex, FranciaországNo longer taking part
- Centre Hospitalier Regional De MarseilleMarseille, FranciaországNo longer taking part
- Robert Debre University HospitalParis, FranciaországNo longer taking part
- Trousseau HospitalParis, FranciaországNo longer taking part
- Hopital Des EnfantsToulouse Cedex 9, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly & Co.
- Trial code
- EU 2023-507655-30-00
- Record updated
- 2026. augusztus 18.
- Original description
1. To demonstrate that tirzepatide MTD is superior to placebo for achieving BMI reduction.Read full original descriptionShow less
I8F-MC-GPIX: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
1. To demonstrate that tirzepatide MTD is superior to placebo for achieving BMI reduction.
2. To demonstrate that tirzepatide MTD is superior to placebo for improvement in weight-related comorbidities.
Inclusion: Be 12 to 17 years; Have a BMI equal to or above the 95th percentile for age and sex on CDC-NCHS 2022.
Exclusion: Have had or plan to have a surgical treatment for obesity; Have Type 1 Diabetes; Have Type 2 Diabetes; Have history of an inflamed pancreas (pancreatitis).